Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1986 Jan;21(1):1–5. doi: 10.1007/BF00199369

Long-term (5–11 years) follow-up of general immune competence in breast cancer

I. Pre-treatment levels with reference to micrometastasis

Hari S Shukla 1, Leslie E Hughes 1,✉, Robert H Whitehead 1, Robert G Newcombe 2
PMCID: PMC11038686  PMID: 3632914

Abstract

General immune competence was measured before treatment in 185 breast cancer patients. They were then followed for 5 to 11 years to determine its relationship to recurrence and its clinical value in predicting prognosis. The tests of immune competence used were immunoglobulins IgG, IgA, IgM, leucocyte counts, percentage and total lymphocyte counts and Mantoux and DNCB skin hypersensitivity tests.

None of these tests was strongly predictive of recurrence on an individual basis, a finding similar to our results at 2 years. The longer period of follow-up now reported has provided no findings of unequivocal statistical significance, but suggests a biphasic host response to early tumours. The patients who developed recurrence within 5–11 years due to micrometastasis had higher lymphocyte counts in their preoperative assessment than patients who remained recurrence free. This suggests that small tumour volumes do not stimulate immunity and that large volumes depress it; tumours in between these groups are associated with higher levels. Examination of studies by a number of authors reveal parallel findings which have not been previously noted. It is not possible to confirm the significance of these findings from this study because of the heterogeneity of human breast cancer. However, if they indicate a general principle of a dynamic host-tumour interplay they have important implications for assessing immune competence at any single point of time and for the theory that cancer may arise during an anergic state. We hope that these findings will stimulate other workers to examine host-tumour interaction from this point of view.

Keywords: Breast Cancer, Breast Cancer Patient, Lymphocyte Count, Leucocyte Count, Early Tumour

References

  • 1.Aisenberg AC. Studies on delayed hypersensitivity in Hodgkin's disease. J Clin Invest. 1962;41:1964. doi: 10.1172/JCI104654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Baral E, Blomgren H, Petrini B, Wasserman J, Ogenstad S, Silwersward C. Prognostic relevance of immunologic variables in breast carcinoma. Acta Radio Ther Phys Biol. 1977;16:417. doi: 10.3109/02841867709133963. [DOI] [PubMed] [Google Scholar]
  • 3.Bolton PM, Mander AM, Davidson JM, James SL, Newcombe RG, Hughes LE. Cellular immunity in cancer; comparison of delayed hypersensitivity skin tests in three common cancers. Br Med J. 1975;3:18. doi: 10.1136/bmj.3.5974.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bolton PM, Teasdale C, Mander AM, James SL, Davison JM, Whitehead RH, Newcombe RG, Hughes LE. Immune competence in breast cancer — relationship of pre treatment immunologic tests to diagnosis and tumour stage. Cancer Immunol Immunother. 1976;1:251. [Google Scholar]
  • 5.Broder SL, Walman TA. The suppressor network in cancer. N Engl J Med. 1978;299:1335. doi: 10.1056/NEJM197812142992404. [DOI] [PubMed] [Google Scholar]
  • 6.Cunningham TJ, Dant D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, Horton J. A correlation of DNCB induced delayed cutaneous hypersentitivity reactions and the course of disease in patients with recurrent breast cancer. Cancer. 1976;37:1696. doi: 10.1002/1097-0142(197604)37:4<1696::aid-cncr2820370413>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  • 7.Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;24:362. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 8.Franks CR, Williams Y. Prognostic value of peripheral lymphocyte counts in hormone therapy of advanced breast carcinoma. Br J Cancer. 1976;34:641. doi: 10.1038/bjc.1976.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Humphrey LJ, Singla O, Volenec FJ. Immunologic responsiveness of the breast cancer patients. Cancer 15. 1980;46(4):893. doi: 10.1002/1097-0142(19800815)46:4+<893::aid-cncr2820461307>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 10.Humphrey LJ, Humphrey MA, Singla O, Volence FJ. Immunologic responsiveness of patients with cancer: relationship to tumour type, stage and prognosis. Ann Surg. 1981;198(5):574. doi: 10.1097/00000658-198105000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kopersztych S, Rezkallah MT, Miki SS, Naspitz CK, Mendes NF. Cell mediated immunity in patients with carcinoma. Correlation between clinical stage and immunocompetence. Cancer. 1976;37:724. doi: 10.1002/1097-0142(197609)38:3<1149::aid-cncr2820380316>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 12.Krown S, Pinsley CM, Wanebo HJ, Braun DW, Wong PP, Oettgen HF. Immunologic reactivity and prognosis in breast cancer. Cancer. 1980;46:1746. doi: 10.1002/1097-0142(19801015)46:8<1746::aid-cncr2820460808>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 13.Lee YTN, Sparks FC, Eilber FR, Morton DL. Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer. 1975;35:748. doi: 10.1002/1097-0142(197503)35:3<748::aid-cncr2820350330>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 14.Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965;2:235. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  • 15.Papatestas AE, Kark AE. Peripheral lymphocyte counts in breast carcinoma: An index of immune competence. Cancer. 1974;34:2014. doi: 10.1002/1097-0142(197412)34:6<2014::aid-cncr2820340620>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  • 16.Riesco A. Five year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135. doi: 10.1002/1097-0142(197001)25:1<135::aid-cncr2820250120>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  • 17.Shukla HS, Hughes LE, Whitehead H, Newcombe RG. Longterm follow-up (5–11 years) of general immune competence in breast cancer. II. Sequential analysis in reference to treatment method and recurrence. Cancer Immunol Immunother. 1986;21:6. doi: 10.1007/BF00199369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Simo-Camps E, Anguera A, Vick JMA, Vidal RA, Sola F, Sarrias R, Gumma J, Gri E, Puigdollers JMA. Immunologic impairment in patients with nonlymphoid cancer. Correlation with the tumoral stage, response to treatment and survival. Cancer. 1976;37:724. doi: 10.1002/1097-0142(197602)37:2<724::aid-cncr2820370219>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  • 19.Spielman M, Kitschke HJ, Tietje K. Untersuchungen zur zellularen Immunitat bei Mammakazinompatientinnen. Onkologie. 1982;5:42. [PubMed] [Google Scholar]
  • 20.Stein JA, Adler A, Ben Efraim S, Maor M. Immunocompetence, immunosuppression and human breast cancer. 1. An analysis of their relationship by known parameters of cell mediated immunity in well defined clinical stages of disease. Cancer. 1976;38:1171. doi: 10.1002/1097-0142(197609)38:3<1171::aid-cncr2820380319>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  • 21.Teasdale C, Hillyard JW, Webster DJT, Bolton PM, Hughes LE. Pre treatment general immune competence and prognosis in breast cancer. A prospective 2 year follow-up. Eur J Cancer. 1979;15:975. doi: 10.1016/0014-2964(79)90281-0. [DOI] [PubMed] [Google Scholar]
  • 22.Teasdale C, Hughes LE, Whitehead RH, Newcombe RG. Factors affecting pre treatment immune competence in cancer patients. I. The effects of age, sex and ill health. II. The corrected effect of malignant disease. Cancer Immunol Immunother. 1979;6:89. [Google Scholar]
  • 23.Wanebo HJ, Rosen PP, Thaler T, Urban JA, Oettgen HF. Immunobiology of operable breast cancer. An assessment of biologic risk by immunoparameters. Ann Surg. 1976;184:258. doi: 10.1097/00000658-197609000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Watkins SM. Cancer prognosis predicted by preoperative lymphocyte responsiveness in vitro. Br J Surg. 1976;63:433. doi: 10.1002/bjs.1800630605. [DOI] [PubMed] [Google Scholar]
  • 25.Whitehead RH, Thatcher J, Teasdale C, Roberts GP, Hughes LE. T&B lymphocytes in breast cancer — stage relationship and abrogation of T lymphocyte depression by enzyme treatment in vitro. Lancet. 1976;I:330. doi: 10.1016/s0140-6736(76)90085-4. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES